Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bank of New York Mellon Corp (BNY) vs Medtronic PLC (MDT) Price & Performance

Bank of New York Mellon CorpTrade
Medtronic PLCTrade

Price performance (Past 24H)

Key statistics

Bank of New York Mellon Corp vs Medtronic PLC — how do they compare? Bank of New York Mellon Corp trades at $159.07 (market cap $106.05B), while Medtronic PLC trades at $81.63 (market cap $101.51B). The key difference: Bank of New York Mellon Corp and Medtronic PLC are close in size by market cap, and Medtronic PLC pays the higher dividend (3.63%). Which is the better fit depends on your goals.

BNYMDT
Market Cap
$106.05B$101.51B
Sector
FinancialsHealth
52-Week High
$154.50$105.35
52-Week Low
$95.16$73.75
Dividend Yield
1.37%3.63%
Enterprise Value
$120.25B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bank of New York Mellon Corp

BNY trades at $151.27, down 0.43% on the day, with a bullish technical signal supported by moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue growth has been steady, rising from $16.0B in 2022 to $19.8B in 2025, while net income margin improved to 29.21%. Analyst consensus is mixed with 38% buy ratings but a $156 price target suggesting modest upside. Recent news highlights strong fee income expectations and a planned 19% dividend increase.

BNY demonstrates solid fundamental strength with improving profitability and consistent earnings beats. The stock offers potential upside to analyst targets and dividend growth, but faces risks from high investing cash outflows and competitive pressures. Current valuation metrics appear reasonable relative to historical performance, though investors should monitor Q2 earnings results for confirmation of growth trajectory.

Medtronic PLC

Medtronic (MDT) trades at $83.57, down 0.36% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $97.50. The company reported strong revenue growth to $33.54B in 2025, with net income of $4.66B and a net margin of 13.2%. Recent acquisitions, such as Scientia Vascular (PRNewsWire, 2026-06-12), and consistent earnings beats highlight operational strength and strategic expansion in medical technology.

MDT presents a compelling investment case with a 3.5% dividend yield and undervalued metrics relative to growth, but faces risks from rising debt levels and margin pressures. Analyst sentiment is strongly bullish with 58% buy ratings, though investors should monitor execution on fiscal 2027 guidance and macroeconomic headwinds impacting healthcare spending.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bank of New York Mellon Corp

BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.

Read more on BNY

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT